Literature DB >> 12111784

Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes.

Delphine Boudard1, Christian Vasselon, Marie-Françoise Berthéas, Jérôme Jaubert, Christiane Mounier, Jacqueline Reynaud, Annie Viallet, Sylviane Chautard, Denis Guyotat, Lydia Campos.   

Abstract

Excessive apoptosis is implicated in the pathogenesis of myelodysplastic syndromes (MDS). We assessed by flow cytometry the expression of several members of the Bcl-2 family in bone marrow mononuclear cells (BMMNC) of 168 MDS samples at diagnosis. The proteins studied were Bcl-2, Bcl-xL (anti-apoptotic), Bax, Bad, Bak, and Bcl-xS (pro-apoptotic). The percentage of BMMNC expressing Bcl-2 and Bcl-xL was higher in refractory anemia with excess of blasts (RAEB), RAEB in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML) than in refractory anemia (RA) and RA with ringed sideroblasts (RAS). Conversely pro-apoptotic proteins Bad, Bak, and Bcl-xS were detected in a higher percentage of cells in RA and RAS. RA and RAS were associated with an increased Bcl-xS/Bcl-xL ratio. The expression of anti-apoptotic proteins was also correlated with that of CD34 and P170 and with the percentage of blast cells. Two-color analyses demonstrated that CD34 and Bcl-2 were usually expressed in the same cells. No significant correlation was found with cytogenetic abnormalities. Higher expression of pro-apoptotic Bcl-2-family proteins (Bak, Bad, Bcl-xS) and higher Bcl-xS/Bcl-xL ratio were associated with longer survival and decreased risk of leukemic transformation in univariate analysis, whereas expression of anti-apoptotic proteins was associated with decreased survival. Consequently Bcl-2 proteins expression was well correlated with the International Prognostic Scoring System (IPSS). Our data confirm that the control of apoptosis is deregulated in MDS cells. Moreover, the study of markers such as CD34 (or Bcl-2), Bcl-xL, and Bcl-xS provides additional prognostic information. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111784     DOI: 10.1002/ajh.10108

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  12 in total

1.  Cycling CD34 expression in subpopulations of head and neck squamous cell carcinoma cell lines is involved in radioresistance and change in cytokeratin expression profile.

Authors:  Tobias Ettl; Matthias Hautmann; Torsten E Reichert; Richard Bauer
Journal:  Clin Exp Med       Date:  2016-11-11       Impact factor: 3.984

2.  Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.

Authors:  Yue Zhang; Xiaomei Yan; Goro Sashida; Xinghui Zhao; Yalan Rao; Susumu Goyama; Susan P Whitman; Nicholas Zorko; Kelsie Bernot; Rajeana M Conway; David Witte; Qian-Fei Wang; Daniel G Tenen; Zhijian Xiao; Guido Marcucci; James C Mulloy; H Leighton Grimes; Michael A Caligiuri; Gang Huang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

Review 3.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  Arsenic trioxide as a treatment for myelodysplastic syndrome.

Authors:  Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

Review 5.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

6.  The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes.

Authors:  M Diamantidis; S Dimoudis; Ph Klonizakis; K Badekas; K Koutourli; S Haralambidou-Vranitsa; E Ioannidou-Papagiannaki
Journal:  Hippokratia       Date:  2007-10       Impact factor: 0.471

7.  Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.

Authors:  Christopher I Slape; Jesslyn Saw; Jeremy B M Jowett; Peter D Aplan; Andreas Strasser; Stephen M Jane; David J Curtis
Journal:  Blood       Date:  2012-07-31       Impact factor: 22.113

Review 8.  Implication of microRNAs in the pathogenesis of MDS.

Authors:  Jing Fang; Melinda Varney; Daniel T Starczynowski
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  Serum Bcl-2 Levels in Patients with β-Thalassemia Minor: A Pilot Study.

Authors:  İrfan Yavaşoğlu; Gökhan Sargın; Gürhan Kadıköylü; Aslıhan Karul; Zahit Bolaman
Journal:  Turk J Haematol       Date:  2014-12-05       Impact factor: 1.831

Review 10.  Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.

Authors:  Ali N Chamseddine; Elias Jabbour; Hagop M Kantarjian; Zachary S Bohannan; Guillermo Garcia-Manero
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.